Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial PMID: 37385280 Lancet
This isn't just about weightit's about getting your life back.
GLP-1 receptor agonists and dual amylin co-agonists: Emerging therapies
BGM is needed before meals to give the user the chance to adjust the meal insulin dose if the pre-meal glucose is out of range at the time, while measurements over a few days will show whether the doses active before that meal require adjustment
The mechanisms driving it
Semaglutide has the longest track record and proven cardiovascular outcomes data (SELECT trial)